Immunotech Biopharm (HKSE:06978) Risk Assessment

View and export this data going back to 2020. Start your Free Trial

What is Immunotech Biopharm Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Immunotech Biopharm is: No Data: Cannot be evaluated.

Competitive Comparison of Immunotech Biopharm's Risk Assessment

For the Biotechnology subindustry, Immunotech Biopharm's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunotech Biopharm's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunotech Biopharm's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Immunotech Biopharm's Risk Assessment falls into.

Save Embed

;

Save Embed

;

Immunotech Biopharm (HKSE:06978) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Immunotech Biopharm Risk Assessment Related Terms

Thank you for viewing the detailed overview of Immunotech Biopharm's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunotech Biopharm Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunotech Biopharm Ltd (HKSE:06978) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.1 Kangding Street, 8th Floor, Block 1, Guosheng Technology Park, Beijing Economic-technological Development Area, Beijing, CHN, 100176

Website

https://www.eaal.net

Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series.

Executives

Jung Hyun Chul
Evodevo Ltd
Yan Kaijing	2501 Other
Xi Zang Jia Ze Chuang Ye Tou Zi You Xian Gong Si	2101 Beneficial owner
Jiang Su Ji Chuan Kong Gu Ji Tuan You Xian Gong Si	2201 Interest of corporation controlled by you
Cao Longxiang	2201 Interest of corporation controlled by you
Cao Fei	2201 Interest of corporation controlled by you
Tian Jin Fu Hua De Ke Ji Kai Fa You Xian Gong Si	2501 Other
Yan Xijun	2501 Other
Wu Naifeng	2501 Other
Tasly (hong Kong) Pharmaceutical Investment Limited	2501 Other
Li Yunhui	2501 Other
Hua Run San Jiu Yi Yao Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
China Resources Pharmaceutical Group Limited	2201 Interest of corporation controlled by you
China Resources Company Limited	2201 Interest of corporation controlled by you

Immunotech Biopharm Headlines

No Headlines